Fig 1.
Oncogenic driver mutations in East Asian never-smokers with lung adenocarcinomas. In tumors from 52 patients, 78.8% (41 of 52) harbored EGFR kinase domain mutations, 5.8% (three of 52) harbored EML4-ALK fusions, 3.8% (two of 52) harbored HER2 mutations, and 1.9% (one of 52) harbored KRAS mutations. Only 9.6% (five of 52) of tumors did not harbor any of these known oncogenic driver mutations.